Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance

AstraZeneca plcTrade
Consumer Discretionary Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Consumer Discretionary Select Sector SPDR Fund trades at $119.22. The key difference: AstraZeneca plc pays a 2.01% dividend while Consumer Discretionary Select Sector SPDR Fund pays none, and Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.

AZNXLY
Market Cap
$248.14B
Sector
Health
52-Week High
$209.48$124.52
52-Week Low
$147.06$105.64
Enterprise Value
$275.41B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.

Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.

Consumer Discretionary Select Sector SPDR Fund

XLY trades at $117.89, down 1.49% today, but maintains a bullish technical outlook with strong moving average support. The ETF benefits from positive analyst sentiment with a 100% buy rating and recent coverage highlighting its potential as a 'sleeper ETF' for Q3 2026. Technical indicators show overbought conditions with RSI readings above 70, but the overall trend remains positive with key support at $118.

The consumer discretionary sector faces headwinds from inflation pressures, but XLY's diversified exposure positions it for recovery. Near-term risks include consumer spending sensitivity to economic conditions, while the bullish analyst consensus and technical momentum suggest potential upside if market conditions stabilize.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Consumer Discretionary Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.

Read more on XLY